Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780104 · ClinicalTrials.gov registry record · Phase 1
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
A Phase 1 study of Leukemia and AML, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00780104: Completed Phase 1 study of Leukemia and AML, sponsored by Abramson Cancer Center at Penn Medicine.
NCT00780104 is a Phase 1 study of Leukemia and AML that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 16 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00780104, a Phase 1 study of Leukemia and AML, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk myeloid leukemias.
Conditions Studied
Interventions
- DRUG Rapamycin, Mitoxantrone, Etoposide, Cytarabine
- DRUG Rapamycin + MEC
Study Locations (1)
Pennsylvania
- University of Pennsylvania Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
What the finished NCT00780104 record still lists
NCT00780104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Rapamycin, Mitoxantrone, Etoposide, Cytarabine is the first listed.
NCT00780104 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00780104 about?
NCT00780104 is a clinical study titled "Sirolimus in Combination With MEC in High Risk Myeloid Leukemias". The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk myeloid leukemias.
What is the current status of trial NCT00780104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-07. Estimated completion is 2010-06.
What conditions does trial NCT00780104 study?
This clinical trial studies the following conditions: Leukemia, AML, CML, Myeloid Leukemias.
What interventions are being tested in trial NCT00780104?
The interventions under investigation include: Rapamycin, Mitoxantrone, Etoposide, Cytarabine (DRUG), Rapamycin + MEC (DRUG).
Who is sponsoring clinical trial NCT00780104?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00780104 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00780104's enrollment target sits among peer trials
16 195th of 233 higher than 31 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia